Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Newly Described Type of Immune Cell and T Cells Share Similar Path to Maturity

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
Better understanding of cells' development has implications in study of inflammatory diseases.

Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that protect boundary tissues such as the skin, the lining of the lung, and the lining of the gut from microbial onslaught. They also have shown they play a role in inflammatory disease, when the body’s immune system is too active.

In animal studies, group-2 innate lymphoid cells (ILC2s) confer immunity during a parasitic infection in mice and are also involved in allergic airway inflammation. A team of Perelman School of Medicine, researchers from the Departments of Medicine, Microbiology, Pathology and Laboratory Medicine, and Cancer Biology, found that maturation of ILC2s requires T-cell factor 1 (TCF-1, the product of the Tcf7 gene) to move forward. TCF-1 is protein that binds to specific parts of DNA to control transcription of genetic information from DNA to messenger RNA.

Avinash Bhandoola, PhD, professor of Pathology and Laboratory Medicine, and Qi Yang, PhD, a postdoc in the Bhandoola lab, describe in Immunity that one mechanism used to build ILCs is the same as that in T cells. Both cell types use a protein pathway centered on Notch that the lab of coauthor Warren Pear, MD, PhD, also in the Pathology and Laboratory Medicine, has studied for the last two decades. Other contributing authors are from the laboratory of David Artis, PhD in Microbiology, that are experts in ILC function, and Angela Haczku, MD, PhD, in the Department of Medicine, who focuses on asthma.

But what makes ILCs and T cells different in their final development? T cells are made in the thymus. ILCs don’t need the thymus, but researchers don’t know exactly where they are produced, just that the thymus isn’t essential for their normal development, unlike T cells.

In the Immunity study, mice without the Tcf7 gene also lack ILC2, and were unable to mount an ILC2 immune response. Forced expression of TCF-1 in bone marrow progenitor cells in the mice partially bypassed the requirement for Notch signaling in the generation of ILC2 in the mice. The researchers suggest that transcription factors such as TCF-1 that underlie early steps of T cell development are also implicated in the development of innate lymphoid cells.

The collaborators’ next steps are to better understand the basic steps of ILC development and build mouse models to test ILC function. “We want to know where ILCs develop in the body and what progenitor cells give rise to ILCs.” says Bhandoola. “If we succeed in constructing mouse models missing different types of ILC, our collaborators can use them to better figure out what these cells do, and perhaps eventually how to control them.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Penn Researchers Tame the Inflammatory Response in Kidney Dialysis
Researchers temporarily suppress complement during dialysis to avoid these problems.
Saturday, December 13, 2014
Funding for DNA Vaccines to Fight Infectious Disease
DARPA awards $12 million to Penn-led group to develop synthetic DNA vaccines to fight infectious disease.
Wednesday, October 22, 2014
Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of ALL Patients Studied
University of Pennsylvania and Children's Hospital of Philadelphia studies reveal unprecedented results with investigational therapy made from patients' own immune cells.
Friday, October 17, 2014
T-Cell Therapy Eradicates an Aggressive Leukemia in Two Children
CHOP/Penn Medicine oncology team reports complete remission in pediatric ALL patients.
Tuesday, March 26, 2013
Recently Identified Immune Cells Possible Therapeutic Target for Eczema
The increasing incidence of allergic skin diseases have spurred researchers to look for better ways to control these immune system-based disorders.
Wednesday, February 06, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!